Renal Cancer - Results from #900

First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma. June 2, 2023

The Role of the Pathologist in Renal Cell Carcinoma Management. June 2, 2023

Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease. June 2, 2023

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System. June 1, 2023

A Review of the Recommendations and Strength of Evidence for Clinical Practice Guidelines on the Management of Small Renal Masses. June 1, 2023

Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review. May 31, 2023

Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study. May 31, 2023

2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma. May 30, 2023

Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. May 30, 2023

Role of Radiation in Treatment of Renal Cell Carcinoma. May 30, 2023

ACR Appropriateness Criteria® Staging of Renal Cell Carcinoma: 2022 Update. May 29, 2023

Supervised Learning and Multi-Omics Integration Reveals Clinical Significance of Inner Membrane Mitochondrial Protein (IMMT) in Prognostic Prediction, Tumor Immune Microenvironment and Precision Medicine for Kidney Renal Clear Cell Carcinoma. May 29, 2023

Stimulated Raman histology as a method to determine the adequacy of renal mass biopsy and identify malignant subtypes of renal cell carcinoma. May 26, 2023

Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. May 26, 2023

Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. May 25, 2023

Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma. May 25, 2023

Effects of remote ischemic preconditioning on renal protection in patients undergoing robot-assisted laparoscopic partial nephrectomy. May 24, 2023

TREM-1 as a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma. May 24, 2023

Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population. May 23, 2023

Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. May 23, 2023

Page 46 of 456